Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated albumin
- Development stage
- Unknown
- Lead developer
- Prolong Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Pegylated albumin is a modified human serum albumin (HSA) therapeutic designed to act as a high-oncotic plasma volume expander and microvascular perfusion enhancer. Developed by Prolong Pharmaceuticals (specifically as the candidate PP-007), the drug consists of HSA molecules covalently conjugated with polyethylene glycol (PEG) chains. This PEGylation increases the effective molecular size and oncotic pressure of the albumin while significantly extending its circulatory half-life and reducing its ability to leak through compromised vascular endothelium. The primary clinical focus for pegylated albumin is the treatment of subarachnoid hemorrhage (SAH) and the prevention of delayed cerebral ischemia. By increasing plasma oncotic pressure and viscosity, it facilitates the dilation of microvessels and improves blood flow and oxygen delivery to ischemic brain tissue, thereby mitigating secondary neuronal injury.
- Other names
- PEG-albuminPEG-HSAPEGylated human serum albumin
Beyond the preview
Go deeper on pegylated albumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated albumin.